A.C.M. is supported by K23DK08433 and the Dept. of Medicine, Beth Israel Deaconess Medical Center (BIDMC); R.A.M. is supported by 5K23CA139005 and the Dept. of Medicine, BIDMC, and the Clinical Investigator Training Program: BIDMC, Harvard/MIT Health Sciences and Technology, in collaboration with Pfizer Inc. and Merck & Co. Funding sources had no role in study design, data collection, data analysis, data interpretation, writing of the article, or the decision to submit for publication. Conflict of Interest Disclosure: G.D. and R.M. have no competing interests to declare. A.C.M.: research funding (Proctor & Gamble, Shire and Salix), advisory board (UCB, Abbott), speaker's honorarium (Abbott, Schering-Plough). A.S.C.: speaker's honoraria (Proctor & Gamble, Centocor), advisory board (Abbott, UCB).
Comparative cost-effectiveness of strategies to prevent postoperative clinical recurrence of Crohn's disease†
Article first published online: 8 SEP 2011
Copyright © 2012 Crohn's & Colitis Foundation of America, Inc.
Inflammatory Bowel Diseases
Volume 18, Issue 9, pages 1608–1616, September 2012
How to Cite
Doherty, G. A., Miksad, R. A., Cheifetz, A. S. and Moss, A. C. (2012), Comparative cost-effectiveness of strategies to prevent postoperative clinical recurrence of Crohn's disease. Inflamm Bowel Dis, 18: 1608–1616. doi: 10.1002/ibd.21904
- Issue published online: 9 AUG 2012
- Article first published online: 8 SEP 2011
- Manuscript Accepted: 25 AUG 2011
- Manuscript Received: 29 JUL 2011
Additional Supporting Information may be found in the online version of this article.
|IBD_21904_sm_SuppFig1.eps||301K||Supporting Information Figure 1|
|IBD_21904_sm_SuppTab1.doc||125K||Supporting Information Table 1|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.